CJC-1295 & Ipamorelin & GHRP-2 Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

CJC-1295 & Ipamorelin & GHRP-2 Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

Synthetic hexapeptide GHS-R1a agonist (pralmorelin) that stimulates pulsatile GH release; approved in Japan as a GH-deficiency diagnostic agent.

GHRP-2 binds and activates GHS-R1a, a Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic arcuate neurons. Receptor engagement triggers phospholipase C activation, inositol trisphosphate-mediated intracellular calcium mobilisation, and exocytosis of stored GH. Simultaneously, GHRP-2 potentiates the endogenous GHRH signal in the hypothalamus and partially suppresses somatostatin tone, producing a synergistic amplification of the pulsatile GH release that exceeds either pathway alone. Cortisol and prolactin secretion are also modestly elevated, reflecting broader GHS-R1a expression outside the somatotroph axis.

Molar mass

818.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Gobburu et al. 1999 — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharm Res; PMID 10496658) — COMPONENT-LEVEL (Ipamorelin), NOT blend-level. IV/SC dosing in human volunteers; GH peaks within 15–20 min. No CJC-1295 or GHRP-2 co-administration.
• Pihoker et al. 1997 — Intranasal/oral GHRP-2 in children with short stature (J Endocrinol; PMID 9390009) — COMPONENT-LEVEL (GHRP-2), NOT blend-level. Pediatric diagnostic PK/PD study; no CJC-1295/Ipamorelin co-administration.
• Pihoker et al. 1998 — GHRP-2 IV bolus Phase I PK/PD in children (J Clin Endocrinol Metab; PMID 9543135) — COMPONENT-LEVEL (GHRP-2), NOT blend-level.
• Johansen et al. 1998 — Comparative pharmacokinetic evaluation of GHRP-2 and ipamorelin, incl. nasal absorption (Xenobiotica; PMID 9879640) — COMPONENT-LEVEL (Ipamorelin + GHRP-2 assessed individually side-by-side), NOT a combined-blend or CJC-1295 study.
• Dominikowski et al. 2026 — GH-IGF1-axis performance-enhancing peptides review (Front Endocrinol; PMID 42395176) — States CJC-1295 no-DAC (Mod GRF 1-29) is essentially uncharacterised in peer-reviewed human literature; cited to support NOT asserting the DAC-form's PK data (Teichman et al. 2006, PMID 16352683) for this blend's no-DAC CJC-1295 component.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) by commercial/community convention for this class of GH secretagogues. CJC-1295 (no-DAC/Mod GRF 1-29) itself has no controlled human or animal PK trial (PMID 42395176); Ipamorelin and GHRP-2 individually have published SC/IV/intranasal human PK data. No PK study exists for the three-peptide blend administered together by any route.

CJC-1295 in this blend is the no-DAC (Mod GRF 1-29) form. The frequently-cited Teichman et al. 2006 SC dose-ranging RCT (PMID 16352683; 30–60 μg/kg in healthy adults) characterized the DAC-conjugated long-acting variant — a different, chemically modified compound — not this no-DAC form; its data is not asserted here as evidence for this blend's CJC-1295 component. Ipamorelin: SC administration studied in human volunteers (Gobburu et al. 1999, PK/PD modeling, PMID 10496658). GHRP-2: SC infusion (1 μg/kg/hr for 270 min) studied in healthy males. No published human study of the triple blend via SC, and no controlled human/animal PK trial has been identified for the no-DAC CJC-1295 form specifically (PMID 42395176).

Bioavailability: CJC-1295 (no-DAC/Mod GRF 1-29) SC half-life is NOT established in peer-reviewed literature — PMID 42395176 states this form is essentially uncharacterised in humans, with no controlled human trials; it is understood only qualitatively as short-acting relative to the DAC-conjugated variant (whose own trials report a 5.8–8.1-day half-life via albumin binding — a different compound, not asserted for this blend's CJC-1295 component). Ipamorelin SC half-life ~2 hours (Gobburu et al. 1999). GHRP-2 SC produces dose-dependent GH pulses. All three reach systemic circulation via SC capillary absorption; the CJC-1295 no-DAC number itself is not established.

SC is the dominant commercial/research packaging format for all three components. CJC-1295's Wikipedia infobox lists route of administration as subcutaneous injection (a general fact, not DAC/no-DAC-specific). The triple blend itself has no published human PK data; route inference is from component-level studies, and no controlled PK trial exists for the no-DAC CJC-1295 form specifically.

Ipamorelin: IV administration at 1 μg/kg in human volunteers produced measurable GH peaks within 15–20 min (Gobburu et al. 1999). GHRP-2: IV bolus studied in children with short stature as part of Phase I PK/PD evaluation (Pihoker et al. 1998). CJC-1295 (no-DAC): no published IV human study identified for this form.

Bioavailability: IV provides 100% bioavailability by definition. Ipamorelin IV shows rapid distribution to pituitary target tissues within minutes. GHRP-2 IV bolus reliably releases GH in pediatric subjects.

IV route studied for individual components (Ipamorelin and GHRP-2) in human PK/PD trials. Not a practical research route for the blend; included for PK characterization of components.

GHRP-2: intranasal administration studied in a clinical trial in 15 children with short stature (Pihoker et al. 1997, J Endocrinol). Johansen et al. 1998 (Xenobiotica) comparative PK study reported GHRP-2 intranasal bioavailability ~50% and Ipamorelin intranasal bioavailability ~20%. CJC-1295 (no-DAC): no published intranasal study identified for this form.

Bioavailability: GHRP-2 intranasal bioavailability approximately 50%; Ipamorelin intranasal bioavailability approximately 20%. No published intranasal bioavailability data exist for CJC-1295 in the no-DAC (Mod GRF 1-29) form used in this blend; general peptide-size/proteolytic-susceptibility considerations make nasal-mucosal absorption plausible only at low, unquantified efficiency for a ~29-residue peptide — unrelated to DAC/albumin-binding, which belongs to a different compound and does not apply here.

Intranasal route has published human evidence for GHRP-2 (clinical trial) and Ipamorelin (comparative PK study) as individual agents. The triple blend has not been studied intranasally, and no intranasal CJC-1295 no-DAC data exists in peer-reviewed literature.

GHRP-2: described as effective when administered orally in published clinical literature (Pihoker et al. 1997, J Endocrinol). Ipamorelin and CJC-1295 (no-DAC): no published human oral bioavailability study identified. The triple blend has not been studied via oral route.

Bioavailability: GHRP-2 (hexapeptide) has reported oral activity in clinical studies, though oral bioavailability is lower than injectable routes. Ipamorelin (pentapeptide) and CJC-1295 (no-DAC, ~29-residue GHRH analog) have no published human oral bioavailability data. Peptides are generally susceptible to proteolytic degradation in the GI tract.

Oral route has limited published human evidence only for GHRP-2 as a single agent. Oral stability of peptide bonds in the GI tract is a separate question from oral absorption; GHRP-2's small size (hexapeptide) may partially explain its reported oral activity. The blend as a whole has no oral study data.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendors of this blend commonly advertise ≥99% purity (e.g., Biotech Peptides, PeakForm Peptides). Independent third-party testing (Janoshik Analytical) has been performed on CJC-1295/Ipamorelin blends; a historical batch report (Chameleon Peptides, Janoshik-verified) measured CJC-1295 (mod GRF 1-29) at 5.59 mg and Ipamorelin at 4.54 mg in a labeled blend, indicating actual content may vary from label claims.

Independent labs cited for this compound

No FDA recalls, market withdrawals, or safety alerts specific to a CJC-1295 & Ipamorelin & GHRP-2 blend product were found. None of the three components are FDA-approved drugs, so they do not appear in FDA drug recall databases.

Buyer red-flag checklist

• All three components (CJC-1295, Ipamorelin, GHRP-2) are FDA Category 2 bulk drug substances prohibited for compounding under 503A/503B as of September 29, 2023.
• None of the three components are FDA-approved for any human indication.
• All three components are WADA-prohibited at all times under S2.2.4 (Growth Hormone Releasing Factors).
• FDA cited GHRP-2 for immunogenicity risk, peptide-related impurities, and reports of serious adverse events including death in critically ill subjects.
• FDA cited CJC-1295 for reports of elevated heart rate and systemic vasodilatory reactions.
• Products are commonly sold as 'research chemicals' (RUO) but marketed and used for human administration, creating regulatory and quality-assurance risk.
• Counterfeit and unapproved peptide products have entered the US supply chain via internet and foreign sources, bypassing safeguards.
• No specific FDA import alert names these peptides; enforcement relies on general unapproved-new-drug authorities, creating inconsistent border control.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No systematic independent underdosing prevalence data specific to this triple blend was found. A Janoshik-verified historical batch report for a CJC-1295/Ipamorelin blend (Chameleon Peptides) showed measured amounts of 5.59 mg CJC-1295 and 4.54 mg Ipamorelin, suggesting potential variance from label claims in individual batches, but no aggregate underdosing rate is available.

• FDA Import Alert 66-71 ('Detention Without Physical Examination of Unapproved Human Growth Hormone (HGH)') targets unapproved HGH and related lyophilized powders. While this alert is specific to HGH/somatropin rather than GH secretagogues, CJC-1295/Ipamorelin/GHRP-2 products imported as unapproved drugs for human use may be subject to detention under general unapproved new drug authorities. No import alert naming these specific peptides was found.66-71
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in- and out-of-competition) under S2.2.4 Growth hormone releasing factors of the 2026 WADA Prohibited List. CJC-1295 listed as a GHRH analogue; ipamorelin listed as a growth hormone secretagogue/mimetic; GHRP-2 (pralmorelin) listed as a GH-releasing peptide.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection bias — positive-experience posters overrepresented in community forums
• No controlled human trial exists for the three-peptide combined blend; all efficacy claims are self-reported
• Vendor-affiliated content present in aggregator sources (potential commercial bias)
• Dose and protocol self-reporting without independent verification
• Batch-to-batch variability confounds attribution of adverse events to peptide vs. impurity
• A specific community report of an extreme adverse reaction attributed to one vendor's batch could not be independently verified (over the audit's refute cap) and is NOT asserted here; only the generic, unattributed GI-distress theme above is kept

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research blend combining the GHRH analog CJC-1295 (Mod GRF 1-29) with the secretagogues ipamorelin and GHRP-2. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet